Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis.
J Cyst Fibros
; 10(6): 470-6, 2011 Dec.
Article
em En
| MEDLINE
| ID: mdl-21849264
ABSTRACT
BACKGROUND:
The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF.METHODS:
Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of -1 or less were randomised to receive risedronate 35 mg weekly or placebo, and calcium (1g)+vitamin D(3) (800IU).RESULTS:
At baseline, BMD Z-scores in the risedronate (n=17) and placebo (n=19) groups were similar. By 24 months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. After 24 months treatment, the mean difference (95% CI) in change in LS, TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p=0.03; 4.0% (-0.5, 8.6) p=0.08; and 2.4% (-3.5, 8.2) p=0.41.CONCLUSIONS:
After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Densidade Óssea
/
Ácido Etidrônico
/
Fibrose Cística
/
Conservadores da Densidade Óssea
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Cyst Fibros
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Reino Unido